GLP-1 and peptide YY secretory response after fat load is impaired by insulin resistance, impaired fasting glucose and type 2 diabetes in morbidly obese subjects

Clinical Endocrinology

Volumn 80, Issue 5, 2014, Pages 671-676

  Fernández García, José C ^a,b   Murri, Mora ^a,b   Coin Aragüez, Leticia ^a,b   Alcaide, Juan ^a   El Bekay, Rajaa ^a,b   Tinahones, Francisco J ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BEHENIC ACID; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; LEPTIN; LIGNOCERIC ACID; LINOLEIC ACID; LIPID EMULSION; MYRISTIC ACID; OLEIC ACID; PALMITIC ACID; PEPTIDE YY; STEARIC ACID; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL; LIPID;

ADULT; ARTICLE; BLOOD PRESSURE; BLOOD SAMPLING; BODY FAT; BODY MASS; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DIET RESTRICTION; ENZYME CHEMISTRY; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; LIPID DIET; MALE; MORBID OBESITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; WAIST CIRCUMFERENCE; ANALYSIS; BLOOD; HOMEOSTASIS; MIDDLE AGED;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; LIPIDS; MALE; MIDDLE AGED; OBESITY, MORBID; PEPTIDE YY;

EID: 84898541167     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12221     Document Type: Article

References (40)

1. Suzuki, K., Jayasena, C.N., &, Bloom, S.R., (2011) The gut hormones in appetite regulation. Journal of Obesity, 2011, 528401.
2. Wren, A.M., &, Bloom, S.R., (2007) Gut hormones and appetite control. Gastroenterology, 132, 2116-2130.
3. Kim, B.J., Carlson, O.D., Jang, H.J., et al,. (2005) Peptide YY is secreted after oral glucose administration in a gender-specific manner. Journal of Clinical Endocrinology and Metabolism, 90, 6665-6671.
4. Ahrén, B., (2004) GLP-1 and extra-islet effects. Hormone and Metabolic Research, 36, 842-845.
5. Gutzwiller, J.P., Göke, B., Drewe, J., et al,. (1999) Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut, 44, 81-86.
6. Adrian, T.E., Savage, A.P., Sagor, G.R., et al,. (1985) Effect of peptide YY on gastric, pancreatic, and biliary function in humans. Gastroenterology, 89, 494-499.
7. Batterham, R.L., Cohen, M.A., Ellis, S.M., et al,. (2003) Inhibition of food intake in obese subjects by peptide YY3-36. New England Journal of Medicine, 349, 941-948.
8. Tolhurst, G., Reimann, F., &, Gribble, F.M., (2009) Nutritional regulation of glucagon-like peptide-1 secretion. Journal of Physiology, 587, 27-32.
9. Ballantyne, G.H., (2006) Peptide YY(1-36) and peptide YY(3-36): Part I. Distribution, release and actions. Obesity Surgery, 16, 651-658.
10. English, P.J., Ashcroft, A., Patterson, M., et al,. (2006) Fasting plasma peptide-YY concentrations are elevated but do not rise postprandially in type 2 diabetes. Diabetologia, 49, 2219-2221.
11. Toft-Nielsen, M.B., Damholt, M.B., Madsbad, S., et al,. (2001) Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. Journal of Clinical Endocrinology and Metabolism, 86, 3717-3723.
12. Ranganath, L.R., Beety, J.M., Morgan, L.M., et al,. (1996) Attenuated GLP-1 secretion in obesity: cause or consequence. Gut, 38, 916-919.
13. Outeiriño-Blanco, E., García-Buela, J., Sangiao-Alvarellos, S., et al,. (2011) Growth hormone, ghrelin and peptide YY secretion after oral glucose administration in healthy and obese women. Hormone and Metabolic Research, 43, 580-586.
14. Feinle, C., Chapman, I.M., Wishart, J., et al,. (2002) Plasma glucagon-like peptide-1 (GLP-1) responses to duodenal fat and glucose infusions in lean and obese men. Peptides, 23, 1491-1494.
15. Vollmer, K., Holst, J.J., Baller, B., et al,. (2008) Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes, 57, 678-687.
16. Ørskov, C., Jeppesen, J., Madsbad, S., et al,. (1991) Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. The Journal of Clinical Investigation, 87, 415-423.
17. Vollmer, K., Gardiwal, H., Menge, B.A., et al,. (2009) Hyperglycemia acutely lowers the postprandial excursions of glucagon-like Peptide-1 and gastric inhibitory polypeptide in humans. Journal of Clinical Endocrinology and Metabolism, 94, 1379-1385.
18. American Diabetes Association. (2011) Standards of medical care in diabetes. Diabetes Care, 34, S11-S61.
19. Brotons, C., de la Figuera, M., Franch, J., et al,. (2008) Prediction of glucose and insulin resistance disorders by using anthropometric parameters of central adiposity: PRED-IR study. Medicina Clínica, 131, 366-370.
20. Ascaso, J.F., Romero, P., Real, J.T., et al,. (2001) Insulin resistance quantification by fasting insulin plasma values and HOMA index in a non-diabetic population. Medicina Clínica, 117, 530-533.
21. Elliott, R.M., Morgan, L.M., Tredger, J.A., et al,. (1993) Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. Journal of Endocrinology, 138, 159-166.
22. Herrmann, C., Göke, R., Richter, G., et al,. (1995) Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion, 56, 117-126.
23. Matthews, D.R., Hosker, J.P., Rudenski, A.S., et al,. (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia, 28, 412-419.
24. Nauck, M.A., Vardarli, I., Deacon, C.F., et al,. (2011) Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia, 54, 10-18.
25. Essah, P.A., Levy, J.R., Sistrun, S.N., et al,. (2007) Effect of macronutrient composition on postprandial peptide YY levels. Journal of Clinical Endocrinology and Metabolism, 92, 4052-4055.
26. Helou, N., Obeid, O., Azar, S.T., et al,. (2008) Variation of postprandial PYY 3-36 response following ingestion of differing macronutrient meals in obese females. Annals of Nutrition & Metabolism, 52, 188-195.
27. Beysen, C., Karpe, F., Fielding, B.A., et al,. (2002) Interaction between specific fatty acids, GLP-1 and insulin secretion in humans. Diabetologia, 45, 1533-1541.
28. Migoya, E.M., Bergeron, R., Miller, J.L., et al,. (2010) Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clinical Pharmacology and Therapeutics, 88, 801-808.
29. Pfluger, P.T., Kampe, J., Castaneda, T.R., et al,. (2007) Effect of human body weight changes on circulating levels of peptide YY and peptide YY3-36. Journal of Clinical Endocrinology and Metabolism, 92, 583-588.
30. Legakis, I.N., Tzioras, C., &, Phenekos, C., (2003) Decreased glucagon-like peptide 1 fasting levels in type 2 diabetes. Diabetes Care, 26, 252.
31. Lugari, R., Dell Anna, C., Ugolotti, D., et al,. (2000) Effect of nutrient ingestion on glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and type 2 diabetes. Hormone and Metabolic Research, 32, 424-428.
32. Adam, T.C., &, Westerterp-Plantenga, M.S., (2005) Glucagon-like peptide-1 release and satiety after a nutrient challenge in normal-weight and obese subjects. British Journal of Nutrition, 93, 845-851.
33. Rask, E., Olsson, T., Söderberg, S., et al,. (2001) Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care, 24, 1640-1645.
34. Le Roux, C.W., Batterham, R.L., Aylwin, S.J., et al,. (2006) Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology, 147, 3-8.
35. Lugari, R., Dei Cas, A., Ugolotti, D., et al,. (2004) Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion. Hormone and Metabolic Research, 36, 111-115.
36. Vilsboll, T., Krarup, T., Deacon, C.F., et al,. (2001) Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes, 50, 609-613.
37. Blüher, M., (2010) The distinction of metabolically 'healthy' from 'unhealthy' obese individuals. Current Opinion in Lipidology, 21, 38-43.
38. Barbarroja, N., Lõpez-Pedrea, R., Mayas, M.D., et al,. (2010) The obese healthy paradox: is inflammation the answer? Journal of Biochemistry, 430, 141-149.
39. Tinahones, F.J., Coín-Aragüez, L., Mayas, M.D., et al,. (2012) Obesity-associated insulin resistance is correlated to adipose tissue vascular endothelial growth factors and metalloproteinase levels. BMC Physiology, 12, 4.
40. Vendrell, J., El Bekay, R., Peral, B., et al,. (2011) Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance. Endocrinology, 152, 4072-4079.